Related Experiment Video

Updated: Jan 7, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K

Real world outcomes with the use of Inotuzumab Ozogamicin in relapsed/refractory B cell acute lymphoblastic leukemia

Archita Ravindranath1, Vijay Pandit1, Uday Kulkarni2

  • 1Department of Haematology, Christian Medical College Vellore, Ranipet Campus, Tamil Nadu, India.

Blood Cancer Journal
|December 31, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos
10:46

Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos

Published on: May 23, 2025

849
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Related Experiment Videos

Last Updated: Jan 7, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K
Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos
10:46

Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos

Published on: May 23, 2025

849
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

Articles linked to this work by shared authors, journal, and citation graph.

Denecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study.

Research and practice in thrombosis and haemostasis·2026

A Study of Epidermal Elafin Immunohistochemistry as a Diagnostic Biomarker of Acute Skin GVHD.

Indian journal of dermatology·2026

Outcomes of Adults Age 40 Years and Older With Newly Diagnosed ALL: A Multicenter Registry Analysis From the Hematology Cancer Consortium.

JCO global oncology·2026

Emergency splenectomy in immune thrombocytopenia presenting with intracranial hemorrhage.

Haematologica·2026

Implementation of an in-house real-time PCR assay as a diagnostic tool for Invasive Aspergillosis in haematology patients: a prospective diagnostic accuracy study.

Indian journal of medical microbiology·2026

Retrospective cohort study assessing radiological outcomes and risk factors for progression of femoral head osteonecrosis in children with sickle cell disease, following bisphosphonate therapy, CD-BMAC and proximal femoral reorientation osteotomy.

Journal of children's orthopaedics·2026

A myeloid-dormant metabolic transcriptome identifies a poor-prognosis subgroup in hyperdiploid multiple myeloma with targetable vulnerabilities.

Blood cancer journal·2026

Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study.

Blood cancer journal·2026

Toward more accurate adverse event attribution in multiple myeloma clinical trials.

Blood cancer journal·2026

Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity.

Blood cancer journal·2026

Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma.

Blood cancer journal·2026

Bortezomib in combination with standard-of-care for late active antibody-mediated rejection with de novo donor-specific antibodies after kidney transplantation: a multicenter randomized trial.

Transplant international : official journal of the European Society for Organ Transplantation·2026

From rejection to vasculopathy: a review of non-invasive biomarkers in alloimmune responses in heart transplantation.

Frontiers in medicine·2026

Immune remodeling after thymectomy in patients with anti-AChR antibodies.

Frontiers in immunology·2026

Exercise-Mobilized Donor Lymphocytes Enhance Blinatumomab Activity Against B-ALL.

Research square·2026

Peptide-HLA II interaction prediction for post-translationally modified peptides.

bioRxiv : the preprint server for biology·2026

Oligomannose Fc Glycans Reprogram the Energetic and Conformational Basis of CD16a Recognition.

bioRxiv : the preprint server for biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us